Michael J. Cork, BSc, MB, PhD, FRCP; Eric L. Simpson, MD, MCR; Jeffrey M. Weinberg, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Michael J. Cork, BSc, MB, PhD, FRCP
Head, Sheffield Dermatology Research
Department of Infection, Immunity & Cardiovascular Disease
Faculty of Medicine, Dentistry and Health
The University of Sheffield Medical School
Sheffield, United Kingdom
Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA
Jeffrey M. Weinberg, MD
Associate Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, USA
Director, Division of Dermatology
Jamaica Hospital Medical Center
Richmond Hill, New York, USA
The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.
Statement of Need/Program Overview
Atopic dermatitis is a chronic inflammatory condition that primarily manifests in the skin, although studies continue to elucidate effects in other organ systems throughout the body.1 An increasing prevalence over the last 2 decades has added to tremendous disease-related burdens faced by patients, family members, and caregivers.1,2 Current insights into atopic dermatitis pathophysiology and its widespread effects on patient health and quality of life support efforts to accelerate diagnoses and proactive management.3,4 Moreover, research into the dysregulated cellular and molecular immune processes underlying the pathogenesis and progression of atopic dermatitis has led to new approaches to disease characterization and treatment.5,6 This Interactive Exchange™ program will open with a brief 3D-animated video focused on the pathophysiologic underpinnings of atopic dermatitis. Expert faculty will then discuss best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options for patients with moderate-to-severe disease. With an overall goal of improving patient outcomes, this educational session has been designed to allow internationally recognized experts to translate the latest published evidence into actionable recommendations for individualized patient care.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
- Sidbury R, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2): 327-349.
- Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.
- Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
After completing this activity, the participant should be better able to:
- Discuss pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, including potential treatment targets
- Evaluate patients with atopic dermatitis over time for persistent symptoms, comorbidities, and treatment responses
- Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis
- Tailor long-term therapy for moderate-to-severe atopic dermatitis to prevent exacerbations, maximize health-related quality of life, manage comorbidities, and minimize adverse events
- Educate patients and caregivers to improve their understanding of atopic dermatitis, provide Action Plans to reduce exacerbations, and promote shared decision-making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to receive credit, participants must complete the pre-assessment questions, view the activity in its entirety, complete the post-test, and program evaluation. Participants must also score at least 70% on the post-test. You will receive a digital copy of your credit certificate at the conclusion of the activity.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v126.96.36.199 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v188.8.131.52 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Michael J. Cork, BSc, MB, PhD, FRCP Consultant/Independent Contractor: AbbVie Inc., Astellas Pharma US, Inc., GlaxoSmithKline plc, Hyphens Pharma Pte Ltd., Johnson & Johnson Services, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC.; Grant/Research Support: Astellas Pharma US, Inc., Johnson & Johnson Services, Inc., LEO Pharma Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC.; Honoraria: AbbVie Inc., Astellas Pharma US, Inc., GlaxoSmithKline plc, Hyphens Pharma Pte Ltd., Johnson & Johnson Services, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC.
Eric L. Simpson, MD, MCR Consultant/Independent Contractor: Celgene Corporation, Dermira, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline plc, Pfizer Inc., sanofi-aventis U.S. LLC; Grant/Research Support: Celgene Corporation, Dermira, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline plc, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Royalty: Regeneron Pharmaceuticals, Inc.
Jeffrey M. Weinberg, MD Grant/Research Support: Regeneron Pharmaceuticals, Inc.
The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Andrea Funk Nothing to disclose
Ashley Marostica, RN, MSN Nothing to disclose
Jim Kappler, PhD Nothing to disclose
Rose O’Connor, PhD, CHCP Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 1.00
credit type CME
Targeting Immune Dysregulation and Delivering Comprehensive Care